Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.45 – $1.99
49% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $5.3K | $5.3K | $5.3K | $6.7K | $8.0K | $97.5K | $92.2K | $87.8K |
| Gross profit | −$5.3K | −$5.3K | −$5.3K | −$6.7K | −$8.0K | −$97.5K | −$92.2K | −$87.8K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $0 | $0 | $0 | $779.3K | $2.5M | $269.8K | $14.0K | $6.6K |
| Operating income | −$5.5K | −$5.5K | −$4.6M | −$5.0M | −$4.5M | −$1.9M | −$2.4M | −$1.5M |
| EBITDA | −$8.7K | −$150 | −$4.6M | −$5.2M | −$4.4M | −$2.5M | −$2.3M | −$1.4M |
| Net income | −$29.9K | $332.0K | −$4.7M | −$5.3M | −$5.4M | −$4.0M | −$3.6M | −$2.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | 0.15 | -205.50 | -5.64 | -1.44 | -1.32 | -0.60 | -0.00 |
Annual figures · source: Financial Modeling Prep
CURATIVE BIOTECHNLOGY INC
No one on the platform currently holds CUBT.
No tracked institution reports a position in CUBT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-03-23 | 1-for-150reverse |
| 2007-11-29 | 10-for-1 |
| 2004-05-21 | 1-for-1000reverse |
No one on the platform has traded CUBT yet.
| +0.00% |
| $5M |
| — |
| FAMDFFutura Medical plc | $0.00 | -70.00% | $712597 | — |
| GLWLFGlow Lifetech Corp. | $0.03 | +0.00% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$CUBT Phase 1 start announcement coming soon imo. $SNY $PFE $MRNA
View on StockTwits ↗$CUBT $12-$54 Share Price soon! Reasons > Predictions
View on StockTwits ↗$CUBT Get ready imo. CUBT nice bio news today-this is a multi $BILLION market and 2 things are obvious to me. One, their drug pipeline is legit as they are starting to partner with multiple entities to develop their eye drug pipeline. And two, CUBT is ramping up their R & D and is getting ready to begin trials in this space. Which means financing has to be close. If so, this is easily a $BILLION or multi $BILLION company. https://www.otcmarkets.com/stock/CUBT/news/Curative-Biotechnology-Advances-Translational-Ophthalmology-Program-Through-PennVet-Research-Agreement?id=520425
View on StockTwits ↗$CUBT Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement | Taiwan News | May. 7, 2026 19:00 https://share.google/85LN2PHGyHZol0AoT
View on StockTwits ↗$CUBT Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy The manufacturing engagement is expected to support both the Company’s planned Phase 1 human clinical study in dry Age-Related Macular Degeneration (AMD) and its clinical K9 study targeting PDE6-associated retinal degeneration. https://finance.yahoo.com/sectors/healthcare/articles/curative-biotechnology-engages-sterling-pharmaceutical-120800618.htm
View on StockTwits ↗$CUBT Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy https://share.google/7dcLJo2F2uZJ2N7P0
View on StockTwits ↗https://curativebiotech.com Research and pilot clinical studies suggest that adding ($CUBT ) IMT504 as an adjuvant can significantly enhance the effectiveness of the $SNY SanofI Pasteur Vero rabies vaccine (Verorab®), particularly by allowing for a lower dose of antigen. Benefits of IMT504 as an Adjuvant Dose Sparing: Studies in both rats and humans showed that a vaccine diluted to 1/5 of its original strength, when combined with IMT504, remained highly effective. In rat models, protection was maintained even at dilutions as high as 1/625. Faster & Higher Antibody Response: Human volunteers receiving the IMT504-adjuvanted diluted vaccine developed protective antibody levels (≥0.5 IU/ml) faster than those receiving non-adjuvanted versions. Potential for Fewer Injections https://ri.conicet.gov.ar/bitstream/handle/11336/67890/CONICET_Digital_Nro.f426a143-8c88-4773-941b-cfdd6658ec42_A.pdf?sequence=2&isAllowed=y
View on StockTwits ↗$CUBT Analyze this chart. Thoughts on their strategy. Looks like their next 48-60 month vision.
View on StockTwits ↗$CUBT the fact they only did a 150-1 split tells me they have upside from 1.00 and this is undervalued . Let’s see
View on StockTwits ↗$CUBT Phase 1 Valuation potential is a range of $12 to $54 per share.
View on StockTwits ↗$CUBT Dual Human and Canine efforts. Phase 1 success is very likely due to metformin vast safety profile. Phase 1 itself could be its sole inflection point.
View on StockTwits ↗$CUBT https://curativebiotech.com/k9-retinal-program
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.